News Release Details

ROCKVILLE, Md.--(BUSINESS WIRE)--Sep. 4, 2009-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conference during the month of September 2009.

• The 11^th Annual Rodman & Renshaw Healthcare Conference
  New York, NY.
  September 9, 2009
  Presentation Time: 10:00 AM Eastern

During this presentation, a member of the company’s senior management team will provide a corporate overview, including a discussion of product development programs, recent corporate activities and financial performance.

A webcast of these presentations will be available both live and by replay, accessible from the company’s website www.emergentbiosolutions.com under “Investors”.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Source: Emergent BioSolutions Inc.

Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com